2024
The forecasted prevalence of comorbidities and multimorbidity in people with HIV in the United States through the year 2030: A modeling study.
Althoff K, Stewart C, Humes E, Gerace L, Boyd C, Gebo K, Justice A, Hyle E, Coburn S, Lang R, Silverberg M, Horberg M, Lima V, Gill M, Karris M, Rebeiro P, Thorne J, Rich A, Crane H, Kitahata M, Rubtsova A, Wong C, Leng S, Marconi V, D'Souza G, Kim H, Napravnik S, McGinnis K, Kirk G, Sterling T, Moore R, Kasaie P. The forecasted prevalence of comorbidities and multimorbidity in people with HIV in the United States through the year 2030: A modeling study. PLOS Medicine 2024, 21: e1004325. PMID: 38215160, PMCID: PMC10833859, DOI: 10.1371/journal.pmed.1004325.Peer-Reviewed Original ResearchConceptsHistory of injection drug useInjection drug useHealthcare needsPrevalence of comorbiditiesHIV diagnosisNorth American AIDS Cohort CollaborationDrug useAntiretroviral therapyHIV surveillance dataGuideline-recommended careNon-Hispanic whitesPrevalence of anxietyChronic kidney diseaseMyocardial infarctionPrevalence of cancerEnd-stage liver diseaseResearch and DesignMultimorbidity prevalenceRisk of comorbiditiesUnited StatesBlack MSMNon-HispanicSubspecialty careClinical capacityHIV clinicians
2022
A Systematic Review of Risk Factors for Suicide Among Persons Living with HIV (1996–2020)
Smith A, Breazeale S, Goulet JL, Vlahov D, Justice AC, Womack JA. A Systematic Review of Risk Factors for Suicide Among Persons Living with HIV (1996–2020). AIDS And Behavior 2022, 26: 2559-2573. PMID: 35107660, DOI: 10.1007/s10461-022-03591-y.Peer-Reviewed Original ResearchConceptsRisk factorsHIV-specific risk factorsInjection drug useHIV-1 RNACause of morbidityShare risk factorsPrevious suicide attemptsQuantitative study designHIV diagnosisPeer-reviewed journalsHIV infectionEligible studiesInclusion criteriaPsychiatric illnessElevated riskGeneral populationAlcohol misuseElectronic databasesDrug useSystematic reviewSuicide attemptsStudy designInitial searchSearch termsHIV
2021
Brief original report: Does smoking status provide information relevant to screening for other substance use among US adults?
Khan MR, Ban K, Caniglia EC, Edelman JE, Gaither J, Crystal S, Chichetto NE, Young KE, Tate J, Justice AC, Braithwaite RS. Brief original report: Does smoking status provide information relevant to screening for other substance use among US adults? Preventive Medicine Reports 2021, 23: 101483. PMID: 34345578, PMCID: PMC8319511, DOI: 10.1016/j.pmedr.2021.101483.Peer-Reviewed Original ResearchInjection drug useUnhealthy alcohol useTobacco screeningDrug useSubstance useOpioid useStimulant useAlcohol useCrack/cocaine useIllicit opioid useCrack/cocaineTest performance characteristicsFormer smokersCurrent smokingSmoking statusUS adultsLifetime smokingCocaine useSmokingScreening resultsFour-fold decreaseNegative resultsMarijuana usePositive resultsTwo-fold decrease
2019
Life-Expectancy Disparities Among Adults With HIV in the United States and Canada: The Impact of a Reduction in Drug- and Alcohol-Related Deaths Using the Lives Saved Simulation Model
Althoff KN, Chandran A, Zhang J, Arevalo WM, Gange SJ, Sterling TR, Gill MJ, Justice AC, Palella FJ, Rebeiro PF, Silverberg MJ, Mayor AM, Horberg MA, Thorne JE, Rabkin CS, Mathews WC, Klein MB, Humes E, Lee J, Hogg R, Moore RD, Research and Design of IeDEA N. Life-Expectancy Disparities Among Adults With HIV in the United States and Canada: The Impact of a Reduction in Drug- and Alcohol-Related Deaths Using the Lives Saved Simulation Model. American Journal Of Epidemiology 2019, 188: 2097-2109. PMID: 31602475, PMCID: PMC7036649, DOI: 10.1093/aje/kwz232.Peer-Reviewed Original ResearchConceptsAlcohol-related deathsInjection drug useKey populationsLife expectancyDrug useHuman immunodeficiency virusLife expectancy benefitAge 20 yearsCause of deathCurrent opioid epidemicAlcohol-related mortalityAntiretroviral treatmentImmunodeficiency virusOpioid epidemicExpected life expectancyWhite womenSubstance useWhite menComparison groupDrugsDeathPLWHLife expectancy disparityMenBlack men
2018
Past year and prior incarceration and HIV transmission risk among HIV-positive men who have sex with men in the US*
Khan MR, McGinnis KA, Grov C, Scheidell JD, Hawks L, Edelman EJ, Fiellin DA, McInnes DK, Braithwaite RS, Justice AC, Wang EA. Past year and prior incarceration and HIV transmission risk among HIV-positive men who have sex with men in the US*. AIDS Care 2018, 31: 349-356. PMID: 30064277, PMCID: PMC6699634, DOI: 10.1080/09540121.2018.1499861.Peer-Reviewed Original ResearchConceptsHIV-positive MSMSex risk behaviorsViral loadSubstance useDrug useRisk behaviorsNon-injection drug useTransmission riskMultiple sex partnershipsDetectable viral loadHIV viral loadHIV transmission riskInjection drug useNew HIV infectionsHIV-positive menPrior incarcerationHealth care programsHIV infectionClinical outcomesPast yearCare programSociodemographic factorsSocial determinantsRisk determinantsMSMRecent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV
Elion RA, Althoff KN, Zhang J, Moore RD, Gange SJ, Kitahata MM, Crane HM, Drozd DR, Stein JH, Klein MB, Eron JJ, Silverberg MJ, Mathews WC, Justice AC, Sterling TR, Rabkin CS, Mayor AM, Klein DB, Horberg MA, Bosch RJ, Eyawo O, Palella FJ. Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 78: 62-72. PMID: 29419568, PMCID: PMC5889316, DOI: 10.1097/qai.0000000000001642.Peer-Reviewed Original ResearchConceptsFramingham risk scoreEffect of abacavirMyocardial infarctionHazard ratioHepatitis C virus infectionType 1Type 2 myocardial infarctionCrude hazard ratioC virus infectionIncident myocardial infarctionInjection drug useHistory of AIDSUse increases riskMarginal structural modelsCohort CollaborationLow CD4Antiretroviral therapyKidney functionMI outcomesTime-dependent confoundingRisk factorsMI occurrenceVirus infectionIncrease riskRisk score
2016
Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy
Trickey A, May MT, Vehreschild J, Obel N, Gill MJ, Crane H, Boesecke C, Samji H, Grabar S, Cazanave C, Cavassini M, Shepherd L, Monforte A, Smit C, Saag M, Lampe F, Hernando V, Montero M, Zangerle R, Justice AC, Sterling T, Miro J, Ingle S, Sterne JA, Collaboration A. Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy. PLOS ONE 2016, 11: e0160460. PMID: 27525413, PMCID: PMC4985160, DOI: 10.1371/journal.pone.0160460.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyLow CD4 countHIV-positive patientsAntiretroviral therapyCD4 countDrug useAntiretroviral Therapy Cohort CollaborationFive-year mortality riskAIDS infectionOlder ageCause-specific mortality rate ratiosNon-AIDS cancerLiver-related mortalityHIV Cohort StudyInjection drug useHIV-1 RNAMortality rate ratiosLiver-related diseasesHigh subsequent mortalityCohort CollaborationLow CD4Prior AIDSCardiovascular mortalityCohort studyPrognostic factors
2015
Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals
May MT, Justice AC, Birnie K, Ingle SM, Smit C, Smith C, Neau D, Guiguet M, Schwarze-Zander C, Moreno S, Guest JL, Monforte A, Tural C, Gill MJ, Bregenzer A, Kirk O, Saag M, Sterling TR, Crane HM, Sterne JA. Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2015, 69: 348-354. PMID: 25848927, PMCID: PMC4506784, DOI: 10.1097/qai.0000000000000603.Peer-Reviewed Original ResearchConceptsInjection drug useDrug useLiver-related mortalityHepatitis C infectionEffect of HCVMortality hazard ratioNorth American cohortHCV coinfectionHCV statusAntiretroviral therapyC infectionHepatitis CHazard ratioSurvival differencesRisk factorsExcess mortalityPoor survivalRisk groupsHCVAmerican cohortHIVNew treatmentsMortalitySubstantial proportionComplete dataSex Differences in Overall and Cause-Specific Mortality among HIV-Infected Adults on Antiretroviral Therapy in Europe, Canada and the US
Jarrin I, Moreno S, Ingle S, May M, Sterling T, Justice A, Bickel M, Crane H, Mugavero M, De Wolf F, Jung N, Cescon A, Garcia I, Elzi L, Arminio A, Krause M, Smith C, Guest J, Hessamfar M, Gill J, Sterne J, del Amo J. Sex Differences in Overall and Cause-Specific Mortality among HIV-Infected Adults on Antiretroviral Therapy in Europe, Canada and the US. Antiviral Therapy 2015, 20: 21-28. PMID: 24675571, DOI: 10.3851/imp2768.Peer-Reviewed Original ResearchConceptsNon-AIDS mortalityInjection drug useAll-causeAntiretroviral therapyAIDS-mortality rateNon-AIDS-related mortalityCause-specific mortalityCD4(+) T-cell countsNon-AIDS infectionsRates of all-causeNon-AIDS malignanciesART Cohort CollaborationT-cell countsHIV-infected adultsHIV-positive patientsHIV-1 RNAAll-cause mortalityCox proportional hazards modelsCohort of individualsHIV-positive menProportional hazards modelART-CCSex differencesCART initiationCause-specific
2013
Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada
Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, Burchell AN, Cohen M, Gebo KA, Gill MJ, Justice A, Kirk G, Klein MB, Korthuis PT, Martin J, Napravnik S, Rourke SB, Sterling TR, Silverberg MJ, Deeks S, Jacobson LP, Bosch RJ, Kitahata MM, Goedert JJ, Moore R, Gange SJ, Research and Design of IeDEA F. Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada. PLOS ONE 2013, 8: e81355. PMID: 24367482, PMCID: PMC3867319, DOI: 10.1371/journal.pone.0081355.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyHIV-positive adultsMortality rateLife expectancyNorth American AIDS Cohort CollaborationHIV transmission risk groupTransmission risk groupsCombination antiretroviral therapyInjection drug useHIV-positive individualsCrude mortality rateComparable life expectancyBaseline CD4Cohort CollaborationART initiationCD4 countAge-specific mortality ratesRisk groupsPositive adultsGeneral populationDrug useAge 20Cells/AdultsAdditional year
2011
Risk Factors for Tuberculosis After Highly Active Antiretroviral Therapy Initiation in the United States and Canada: Implications for Tuberculosis Screening
Sterling TR, Lau B, Zhang J, Freeman A, Bosch RJ, Brooks JT, Deeks SG, French A, Gange S, Gebo KA, Gill M, Horberg MA, Jacobson LP, Kirk GD, Kitahata MM, Klein MB, Martin JN, Rodriguez B, Silverberg MJ, Willig JH, Eron JJ, Goedert JJ, Hogg RS, Justice AC, McKaig RG, Napravnik S, Thorne J, Moore RD. Risk Factors for Tuberculosis After Highly Active Antiretroviral Therapy Initiation in the United States and Canada: Implications for Tuberculosis Screening. The Journal Of Infectious Diseases 2011, 204: 893-901. PMID: 21849286, PMCID: PMC3156918, DOI: 10.1093/infdis/jir421.Peer-Reviewed Original ResearchConceptsActive antiretroviral therapy (HAART) initiationAntiretroviral therapy initiationInjection drug useHIV-1 RNAHuman immunodeficiency virusHAART initiationTuberculosis riskBaseline CD4Therapy initiationMale sexNonwhite raceHispanic ethnicityDrug useBaseline HIV-1 RNAMonths of HAARTLow-incidence settingsProportional hazards modelActive tuberculosisLymphocyte countParametric survival modelsTuberculosis screeningImmunodeficiency virusBlack raceLymphocytes/Risk factors
2010
Decreased Serum Antibody Responses to Recombinant Pneumocystis Antigens in HIV-Infected and Uninfected Current Smokers
Crothers K, Daly KR, Rimland D, Goetz MB, Gibert CL, Butt AA, Justice AC, Djawe K, Levin L, Walzer PD. Decreased Serum Antibody Responses to Recombinant Pneumocystis Antigens in HIV-Infected and Uninfected Current Smokers. MSphere 2010, 18: 380-386. PMID: 21191078, PMCID: PMC3067379, DOI: 10.1128/cvi.00421-10.Peer-Reviewed Original ResearchConceptsRespiratory syncytial virusChronic obstructive pulmonary diseaseAntibody responseEnzyme-linked immunosorbent assayP. jiroveciiCurrent smokersSerum antibodiesHIV-negative subjectsObstructive pulmonary diseaseInjection drug useSerum antibody responseMultivariate Tobit regression modelsHazardous alcohol useCross-sectional analysisUninfected patientsCurrent smokingHIV infectionIndependent predictorsPulmonary diseaseSyncytial virusImmunosuppressive effectsSerologic studiesSubsequent riskPneumocystis jiroveciiDrug use
2009
Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries
Zwahlen M, Harris R, May M, Hogg R, Costagliola D, de Wolf F, Gill J, Fätkenheuer G, Lewden C, Saag M, Staszewski S, d'Arminio Monforte A, Casabona J, Lampe F, Justice A, von Wyl V, Egger M. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. International Journal Of Epidemiology 2009, 38: 1624-1633. PMID: 19820106, PMCID: PMC3119390, DOI: 10.1093/ije/dyp306.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAnti-Retroviral AgentsAntiretroviral Therapy, Highly ActiveCause of DeathCD4 Lymphocyte CountCohort StudiesFemaleHIVHIV InfectionsHomosexuality, MaleHumansMaleMortalityPrevalenceProspective StudiesRisk FactorsSubstance Abuse, IntravenousViral LoadVirus ReplicationConceptsCD4 cell countAntiretroviral therapyCells/microLGeneral populationCell countEligible patientsExcess mortalityCopies/Start of ARTViral replicationART Cohort CollaborationCorresponding general populationMortality of HIVPotent antiretroviral therapyCombination antiretroviral therapyPercentage of patientsProspective cohort studyInjection drug useViral load measurementsNumber of deathsCohort CollaborationCohort studyMedian ageViral loadClinical stage
2007
Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies
May M, Sterne JA, Sabin C, Costagliola D, Justice AC, Thiébaut R, Gill J, Phillips A, Reiss P, Hogg R, Ledergerber B, D'Arminio Monforte A, Schmeisser N, Staszewski S, Egger M. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 2007, 21: 1185-1197. PMID: 17502729, PMCID: PMC3460385, DOI: 10.1097/qad.0b013e328133f285.Peer-Reviewed Original ResearchConceptsStart of HAARTCD4 cell countCell countHIV-1 RNA levelsHIV-1-infected patientsInitiation of HAARTTreatment-naive patientsDiagnosis of AIDSInjection drug useVirological responseHIV careNew AIDSCumulative incidenceParametric survival modelsClinical stageProspective studyRisk calculatorHAARTProgression rateTreatment changesPatientsDrug usePrognostic modelAIDSCells/
2006
Increased COPD Among HIV-Positive Compared to HIV-Negative Veterans
Crothers K, Butt AA, Gibert CL, Rodriguez-Barradas MC, Crystal S, Justice AC, Team F. Increased COPD Among HIV-Positive Compared to HIV-Negative Veterans. CHEST Journal 2006, 130: 1326-1333. PMID: 17099007, DOI: 10.1378/chest.130.5.1326.Peer-Reviewed Original ResearchConceptsInjection drug usePrevalence of COPDHIV-negative subjectsIndependent risk factorHIV infectionICD-9 codesRisk factorsDiagnostic codesAlcohol abuseICD-9 diagnostic codesHIV-negative veteransActive antiretroviral therapyHIV-positive patientsEra of HAARTHIV-negative menHIV-positive subjectsProspective observational studyPathogenesis of COPDRisk of COPDHealth care providersElectronic medical recordsRace/ethnicityAntiretroviral therapyHIV-positiveCigarette smokingHealth‐Related Quality of Life in Veterans and Nonveterans with HIV/AIDS
Mrus JM, Leonard AC, Yi MS, Sherman SN, Fultz SL, Justice AC, Tsevat J. Health‐Related Quality of Life in Veterans and Nonveterans with HIV/AIDS. Journal Of General Internal Medicine 2006, 21: s39-s47. PMID: 17083499, PMCID: PMC1924783, DOI: 10.1111/j.1525-1497.2006.00644.x.Peer-Reviewed Original ResearchConceptsHIV/AIDSSymptom botherDepressive symptomsCorrelates of HRQOLPoorer overall functionDeterminants of HRQoLNon-VA settingsHealth-related qualityInjection drug useRating Scale scoresUnstable housing situationsVeterans Administration settingsQuality of lifeVeteran statusHealth valueOverall functionPoor HRQOLHRQOL outcomesMultivariable analysisHRQOL measuresMultivariable associationsMultivariable modelHRQoLVeteran populationHealth ratingsHepatitis C coinfection is independently associated with decreased adherence to antiretroviral therapy in a population-based HIV cohort
Braitstein P, Justice A, Bangsberg DR, Yip B, Alfonso V, Schechter MT, Hogg RS, Montaner J. Hepatitis C coinfection is independently associated with decreased adherence to antiretroviral therapy in a population-based HIV cohort. AIDS 2006, 20: 323-331. PMID: 16439865, DOI: 10.1097/01.aids.0000198091.70325.f4.Peer-Reviewed Original ResearchConceptsInjection drug useAntiretroviral treatmentAntiretroviral therapyLiver injuryHigher plasma albumin levelCombination antiretroviral treatmentHepatitis C serostatusHepatitis C coinfectionPlasma albumin levelsMultivariate logistic regressionDrug treatment programsHIV/AIDSHCV seropositivityC coinfectionHCV antibodiesHIV cohortHCV serologyAlbumin levelsLow albuminPrimary outcomePrescription refillsPoor adherenceMale genderHIV therapyEligible individuals
2002
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies
Egger M, May M, Chêne G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, Monforte A, de Wolf F, Reiss P, Lundgren JD, Justice AC, Staszewski S, Leport C, Hogg RS, Sabin CA, Gill MJ, Salzberger B, Sterne J, Collaboration T. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. The Lancet 2002, 360: 119-129. PMID: 12126821, DOI: 10.1016/s0140-6736(02)09411-4.Peer-Reviewed Original ResearchConceptsCells/microLCD4 cell countBaseline CD4 cell countActive antiretroviral therapyProbability of progressionCell countAntiretroviral therapyCohort studyBaseline HIV-1 viral loadCD4 cells/microLCD4 cells/microL.HIV-1 viral loadHIV-1-infected patientsART Cohort CollaborationTreatment-naive patientsCells/microL.Dominant prognostic factorFuture treatment guidelinesInjection drug useHigh-risk stratumLow-risk stratumSingle cohort studyCohort CollaborationNew AIDSAdult patients